LU91452I2 - "Mycafungine et ses sels pharmaceutiquement acceptables(MYCAMINEr)" - Google Patents

"Mycafungine et ses sels pharmaceutiquement acceptables(MYCAMINEr)"

Info

Publication number
LU91452I2
LU91452I2 LU91452C LU91452C LU91452I2 LU 91452 I2 LU91452 I2 LU 91452I2 LU 91452 C LU91452 C LU 91452C LU 91452 C LU91452 C LU 91452C LU 91452 I2 LU91452 I2 LU 91452I2
Authority
LU
Luxembourg
Prior art keywords
mycaminer
mycafungin
pharmaceutically acceptable
acceptable salts
salts
Prior art date
Application number
LU91452C
Other languages
English (en)
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26305774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91452(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB9420425A external-priority patent/GB9420425D0/en
Priority claimed from GBGB9508745.8A external-priority patent/GB9508745D0/en
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of LU91452I2 publication Critical patent/LU91452I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
LU91452C 1994-10-07 2008-06-04 "Mycafungine et ses sels pharmaceutiquement acceptables(MYCAMINEr)" LU91452I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9420425A GB9420425D0 (en) 1994-10-07 1994-10-07 New compound
GBGB9508745.8A GB9508745D0 (en) 1995-04-28 1995-04-28 New compound
PCT/JP1995/001983 WO1996011210A1 (fr) 1994-10-07 1995-09-29 Hexapeptides cycliques a activite antibiotique

Publications (1)

Publication Number Publication Date
LU91452I2 true LU91452I2 (fr) 2008-08-04

Family

ID=26305774

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91452C LU91452I2 (fr) 1994-10-07 2008-06-04 "Mycafungine et ses sels pharmaceutiquement acceptables(MYCAMINEr)"

Country Status (26)

Country Link
US (2) US6107458A (fr)
EP (1) EP0788511B1 (fr)
JP (2) JP2897427B2 (fr)
KR (1) KR100353303B1 (fr)
CN (1) CN1203089C (fr)
AR (1) AR041770A1 (fr)
AT (1) ATE229541T1 (fr)
AU (1) AU696949B2 (fr)
BR (2) BR9504791B1 (fr)
CA (1) CA2202058C (fr)
DE (2) DE122008000025I2 (fr)
DK (1) DK0788511T3 (fr)
ES (1) ES2187575T3 (fr)
FI (1) FI119988B (fr)
FR (1) FR08C0028I2 (fr)
HU (1) HU228151B1 (fr)
IL (1) IL115484A (fr)
LU (1) LU91452I2 (fr)
MX (1) MX9702531A (fr)
NL (1) NL300352I2 (fr)
NO (2) NO328483B1 (fr)
OA (1) OA10475A (fr)
PT (1) PT788511E (fr)
RU (1) RU2165423C2 (fr)
TR (1) TR199501229A2 (fr)
WO (1) WO1996011210A1 (fr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696084A (en) * 1996-08-16 1997-12-09 Abbott Laboratories Amino-lipopetide antifungal agents
AUPO371596A0 (en) * 1996-11-19 1996-12-12 Fujisawa Pharmaceutical Co., Ltd. New compound
AUPO381496A0 (en) * 1996-11-25 1996-12-19 Fujisawa Pharmaceutical Co., Ltd. New compound
US6291680B1 (en) * 1997-06-18 2001-09-18 Fujisawa Pharmaceutical Co., Ltd. Production process
HUP0102515A3 (en) * 1998-02-09 2001-12-28 Fujisawa Pharmaceutical Co Cyclopeptides, process for their preparation, pharmaceutical compositions comprising thereof and their use
AU756792B2 (en) * 1998-02-09 2003-01-23 Fujisawa Pharmaceutical Co., Ltd. New compound
US7084279B1 (en) * 1999-02-11 2006-08-01 Emisphere Technologies Inc. Oxadiazole compounds and compositions for delivering active agents
WO2000047188A1 (fr) * 1999-02-11 2000-08-17 Emisphere Technologies, Inc. Composes a base d'oxadiazole et compositions destinees a l'apport d'agents actifs
AUPP999799A0 (en) 1999-04-27 1999-05-20 Fujisawa Pharmaceutical Co., Ltd. New compound
AUPQ066399A0 (en) * 1999-05-31 1999-06-24 Fujisawa Pharmaceutical Co., Ltd. Antifungal combination use
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
AU6564000A (en) * 1999-07-27 2001-02-13 Aventis Pharma Deutschland Gmbh Novel cyclohexapeptide compounds, processes for their production and their use as a pharmaceutical
AUPQ462399A0 (en) * 1999-12-13 2000-01-13 Fujisawa Pharmaceutical Co., Ltd. New use
TWI250992B (en) 2000-02-21 2006-03-11 Astellas Pharma Inc Polypeptide compounds for the prophylactic and/or therapeutic treatment of infectious diseases caused by pathogenic microorganisms
ES2191516B1 (es) * 2000-07-28 2005-01-01 Consejo Superior De Investigaciones Cientificas Antibioticos antifungicos de naturaleza peptidica inhibidores de la germinacion y el crecimiento de hongos fitopatogenos.
AUPQ938700A0 (en) * 2000-08-14 2000-09-07 Fujisawa Pharmaceutical Co., Ltd. Antifungal combination use
DE60234812D1 (de) 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
JP2005053782A (ja) * 2001-08-31 2005-03-03 Fujisawa Pharmaceut Co Ltd 環状リポペプチド化合物の新規結晶
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
JP4784093B2 (ja) * 2002-08-08 2011-09-28 アステラス製薬株式会社 イソオキサゾリル安息香酸の製造法
AU2003903205A0 (en) * 2003-06-23 2003-07-10 Fujisawa Pharmaceutical Co., Ltd. New compound
EP1654036B1 (fr) * 2003-07-22 2007-12-26 Theravance, Inc. Utilisation d'un agent antifongique a base d'echinocandines conjointement avec un agent antibacterien glycopeptidique
WO2005026323A2 (fr) * 2003-09-05 2005-03-24 Merck & Co., Inc. Phases stationnaires et procede de purification mettant en oeuvre lesdites phases
WO2005028438A1 (fr) * 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. Nouveau derive de piperidine
US7476673B2 (en) * 2003-12-30 2009-01-13 Allergan, Inc. Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors
AU2005245470A1 (en) * 2004-05-20 2005-12-01 Foldrx Pharmaceuticals, Inc. 2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
TW200626138A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
AR051026A1 (es) 2004-09-20 2006-12-13 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
WO2006034341A2 (fr) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation en tant qu'agents therapeutiques
BRPI0515482A (pt) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos e seus usos como agentes terapêuticos
MX2007003327A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa.
CA2580855A1 (fr) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation en tant qu'agents therapeutiques
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
WO2006044456A1 (fr) * 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Composes de suppression de non-sens et procedes de leur utilisation
US8541457B2 (en) 2005-06-03 2013-09-24 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors
US7947707B2 (en) * 2005-10-07 2011-05-24 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
CN101516387B (zh) * 2006-07-26 2014-06-04 桑多斯股份公司 卡泊芬净制剂
US8853392B2 (en) 2007-06-03 2014-10-07 Vanderbilt University Benzamide mGluR5 positive allosteric modulators and methods of making and using same
EP2786993B1 (fr) 2007-08-13 2017-11-15 Monsanto Technology LLC Procédé et compositions pour le contrôle de nématodes
TW200934507A (en) * 2007-10-29 2009-08-16 Astellas Pharma Inc Polypeptide compounds
US8034806B2 (en) 2007-11-02 2011-10-11 Vanderbilt University Bicyclic mGluR5 positive allosteric modulators and methods of making and using same
US8362050B2 (en) * 2008-06-24 2013-01-29 Irm Llc Compounds and methods for modulating G protein-coupled receptors
US9394340B2 (en) 2009-03-24 2016-07-19 Cadila Healthcare Limited Purification process for lipopeptides
BR112013023531A2 (pt) 2011-04-04 2016-12-06 Xellia Pharmaceuticals Aps processo de um único vaso para a fabricação de micafungina ou de um sal desta
WO2012143293A1 (fr) 2011-04-20 2012-10-26 Xellia Pharmaceuticals Aps Procédé de purification de la micafongine
CN102775476B (zh) 2011-05-12 2015-01-07 上海天伟生物制药有限公司 一种米卡芬净钠盐的制备方法
EP2709609B1 (fr) 2011-05-17 2017-10-04 Shionogi & Co., Ltd. Composés hétérocycliques
EP2763971B1 (fr) 2011-09-09 2016-06-08 Sandoz AG Préparation d'intermédiares de micafongine
CN102627689B (zh) * 2012-03-30 2014-08-06 上海天伟生物制药有限公司 一种环肽类化合物的水合物及其制备方法和用途
CN102627688B (zh) 2012-03-30 2014-12-31 上海天伟生物制药有限公司 一种高纯度环肽化合物及其制备方法和用途
CN102659930B (zh) 2012-03-30 2014-04-23 上海天伟生物制药有限公司 一种高纯度环肽类物质的晶体及其制备方法和用途
EP3150621A4 (fr) * 2014-05-29 2017-12-27 Shanghai Techwell Biopharmaceutical Co., Ltd Composition de composé peptidique cyclique, son procédé de préparation et ses utilisations
WO2015180682A1 (fr) * 2014-05-29 2015-12-03 上海天伟生物制药有限公司 Solvate d'un composé peptidique cyclique, son procédé de préparation et ses utilisations
WO2016056023A2 (fr) * 2014-10-07 2016-04-14 Alaparthi Lakshmi Prasad Produits intermédiaires et procédés de préparation de micafungine
CA2937365C (fr) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Formulation en granules de 5-methyl-1-phenyl-2-(1h)-pyridone et methode de fabrication associee
PL3554474T3 (pl) 2016-12-16 2024-04-15 Baxter International Inc. Kompozycje mykafunginy
EP3485873A1 (fr) 2017-11-17 2019-05-22 Cadila Healthcare Limited Compositions injectables pharmaceutiques stables de micafungine
CN113087775B (zh) * 2018-05-31 2022-07-08 杭州中美华东制药有限公司 米卡芬净钠新晶型ii及其制备方法
WO2020013116A1 (fr) * 2018-07-10 2020-01-16 京都薬品工業株式会社 Inhibiteur de ptp-1b et son utilisation
CN110734408A (zh) * 2019-10-22 2020-01-31 重庆康乐制药有限公司 一种米卡芬净类衍生物侧链中间体的制备方法
CN115785226B (zh) * 2021-09-09 2026-02-24 上海天伟生物制药有限公司 一种棘白菌素药物杂质及其制备、纯化方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1574603A1 (ru) * 1988-08-11 1990-06-30 Ивановский Химико-Технологический Институт Способ получени мезо-тетраарилоктаметилпорфиринов
IE912046A1 (en) * 1990-06-18 1991-12-18 Fujisawa Pharmaceutical Co New polypeptide compound and a process for preparation¹thereof
IL122315A (en) * 1992-03-19 2002-03-10 Lilly Co Eli Cyclic peptides and antifungal pharmaceutical compositions containing them

Also Published As

Publication number Publication date
PT788511E (pt) 2003-04-30
DE122008000025I1 (de) 2008-08-21
HU228151B1 (en) 2012-12-28
IL115484A (en) 2000-07-16
JP2897427B2 (ja) 1999-05-31
CA2202058A1 (fr) 1996-04-18
AR041770A1 (es) 2005-06-01
KR970707150A (ko) 1997-12-01
WO1996011210A1 (fr) 1996-04-18
MX9702531A (es) 1997-06-28
BR9504791B1 (pt) 2010-10-05
NL300352I2 (nl) 2008-11-03
CA2202058C (fr) 2007-11-06
BRPI9504791B8 (pt) 2019-12-31
DE69529172D1 (de) 2003-01-23
NL300352I1 (nl) 2008-08-01
FI971397L (fi) 1997-05-27
HUT77736A (hu) 1998-07-28
TR199501229A2 (tr) 1996-07-21
EP0788511B1 (fr) 2002-12-11
NO971544D0 (no) 1997-04-04
DE69529172T2 (de) 2003-04-17
ATE229541T1 (de) 2002-12-15
FI119988B (fi) 2009-05-29
AU3578095A (en) 1996-05-02
US6107458A (en) 2000-08-22
ES2187575T3 (es) 2003-06-16
NO328483B1 (no) 2010-03-01
NO2010016I1 (no) 2010-08-16
JPH10507174A (ja) 1998-07-14
CN1203089C (zh) 2005-05-25
BR9504791A (pt) 1996-10-22
FR08C0028I1 (fr) 2008-08-15
RU2165423C2 (ru) 2001-04-20
IL115484A0 (en) 1996-01-19
NO971544L (no) 1997-06-04
DE122008000025I2 (de) 2011-02-17
FR08C0028I2 (fr) 2009-11-20
FI971397A0 (fi) 1997-04-04
HK1004136A1 (en) 1998-11-20
OA10475A (en) 2002-04-08
EP0788511A1 (fr) 1997-08-13
US6265536B1 (en) 2001-07-24
DK0788511T3 (da) 2003-03-31
KR100353303B1 (ko) 2003-01-15
NO2010016I2 (no) 2011-10-17
JP3518665B2 (ja) 2004-04-12
AU696949B2 (en) 1998-09-24
JPH10324695A (ja) 1998-12-08
CN1168675A (zh) 1997-12-24

Similar Documents

Publication Publication Date Title
LU91452I2 (fr) "Mycafungine et ses sels pharmaceutiquement acceptables(MYCAMINEr)"
LU91291I2 (fr) Deferasirox et ses sels pharmaceutiquement acceptables (EXJADEr)
LU90736I2 (fr) Agenerase-amprenavir et ses d-riv-s pharmaceutiquement acceptables
NL300952I2 (nl) Peramivir en farmaceutisch aanvaardbare zouten daarvan
LU91076I2 (fr) Tulathromycin et ses sels pharmaceutiquement acceptables (draxxin).
LU91345I2 (fr) Rufinamide et ses sels pharmaceutiquement acceptables (inovelon)
LU91437I2 (fr) "dabigatran-etexilate et ses sels- particulièrement dabigatran-etexilate-mésilate (PRADAXA)"
LU90829I2 (fr) Tepoxalin-zubrin et ses d-riv-s pharmaceutiquement acceptables
LU91346I2 (fr) Lumiracoxib et ses dérivés pharmaceutiquement acceptables (prexige)
LU90866I2 (fr) Hydrochlorure de sibutramine ses d-riv-s et ses sels pharmaceutiquement acceptables en particulier le monohydrate d'hydrochlorurede sibutramine
LU91205I2 (fr) Ciclesonide et ses dérivés pharmaceutiquement acceptables (alvesco)
LU90844I2 (fr) es Riamet et ses d-riv-s pharmaceutiquement acceptabl
EP0765166A4 (fr) Conjugues radiomarques d'annexine-galactose
LU92564I2 (fr) Médocaril de ceftobiprole et les sels pharmaceutiquement acceptables qui en dérivent
DK0821692T3 (da) Immunopotenserende inosinmonophosphat-5'-nukleotidasemodstandsdygtige derivater og anvendelser deraf
ITGE940099A0 (it) Dispositivo per l'agugliatura di una falda di ovatta.
ITMI962503A0 (it) Procedimento per progettare una apparecchiatura impiegante superconduttivita' e apparecchiatura impiegante superconduttivita'
KR940005143U (ko) 유희용 라켓
ITGE940106A0 (it) Dispositivo per l'agugliatura di una falda di ovatta.
LU90110I2 (fr) Penciclovir et ses dérivés pharmaceutiquement acceptables
FI943875L (fi) 2,3,4,5-Tetrahydro-1H-3-bentsatsepiinejä ja niiden farmaseuttisesti hyväksyttäviä happoadditiosuoloja
KR940001899U (ko) 네온 변압기의 접속구
KR960038365U (ko) 피엘씨의 입출력 증설장치
GB9226874D0 (en) Immunopotentiatory agents and physiologically acceptable salts thereof
ZA937286B (en) Immunopotentiatory agents and physiologically acceptable salts thereof